[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for dual GLP-1/GIP receptor agonist enicepatide in people living with type 2 diabetes and overweight or obesity

Phase 2positiveenicepatidePositive

AI Analysis

Summary

Roche announced positive Phase II results for enicepatide, a dual GLP-1/GIP receptor agonist, in people with type 2 diabetes and overweight or obesity. The positive data advances the compound toward potential further development.

Clinical Trial Data

Phase

Phase II

Outcome Details

Phase II results positive for dual GLP-1/GIP receptor agonist

Importance:7/10

Sentiment:

0.75

Phase 2diabetesobesityGLP-1GIPpositive results

Related Companies

$RHHBY

Read the original article

Published by yahoo_finance on September 22, 2026 5:00 AM

Read Original